Pearce IP is delighted to announce that leading intellectual property specialist Julie Ballance (Patent Attorney, Lawyer and Notary, NZ) commenced with Pearce IP as a Special...
23 OCT 2023 | US | Approval Alert: FDA Approves Celltrion’s Zymfentra® (infliximab-dyyb), Biosimilar to Janssen’s Remicade®, and the First Approved SC Infliximab...
15 OCT 2023 | Samsung Bioepis Reveals SB16 (denosumab) Study Results at ASBMR Samsung Bioepis presented new data on its SB16 (denosumab, biosimilar to Amgen’s Prolia®) at the...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
An Australian Court has found in favour of Globaltech which solved a mining problem with an elegant solution. An important lesson from this decision is that driving IP innovation can be central to maintaining a market-leading position.
07 OCT 2023 | Samsung Bioepis Presents Switching Study Results for SB15, Biosimilar to Regeneron’s Eylea® (aflibercept) Samsung Bioepis announced its Phase III switching study...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
02 OCT 2023 | Nobel Prize Awarded to Katalin Karikó and Drew Weissman for Their Work Which Supported the mRNA COVID-19 Vaccine The Nobel Assembly at Karolinska...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
22 SEP 2023 | KR | Prestige Biologics Partners with Dr. Reddy’s Laboratories Subsidiary in Strategic Manufacturing Collaboration Prestige Biologics, a contract development and...
15 SEP 2023 | US | Novartis Shareholders Approve Sandoz Spin-Off On 15 September 2023, Novartis shareholders approved the proposed Sandoz spin-off, Novartis’ generics and...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
08 SEP 2023 | Coherus Completes Acquisition Of Surface Oncology Coherus Biosciences announced that it completed its acquisition of Surface Oncology, Inc., a clinical-stage...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
01 SEP 2023 | AU | Celltrion Submits Marketing Application For CT-P43, Biosimilar To Janssen’s Stelara® (Ustekinumab) Business Korea reported that Celltrion filed an application...
25 AUG 2023 | US | Celltrion and J&J Reach Patent Settlement Regarding Ustekinumab Korea Biomedical Review reported that Celltrion has finalised an agreement with Johnson...
18 AUG 2023 | US | FDA Approves Regeneron’s 8mg Eylea® (Aflibercept) For wAMD, DME and DR Regeneron announced that the FDA approved its 8mg Eylea® (aflibercept) to treat Wet...
12 AUG 2023 | US | Biocon Confirms Viatris North American Transition Will Complete By End Q3 2023 According to the Business Standard Biocon Biologics’ CEO has confirmed the...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
We are pleased to announce that 3 Pearce IP leaders are ranked amongst the world’s best patent and trade mark practitioners by WIPR Leaders 2023. Pearce IP’s Executives Naomi...
03 AUG 2023 | US | Teva confirms intention to launch US adalimumab biosimilar AVT02 in 2024 Teva’s CEO confirmed that it will still pursue launching its Alvotech...
27 JUL 2023 | EU | New indication alert: AZ’s Soliris® (eculizumab) approved to treat gMG in children aged six to 17 AstraZeneca announced that the EMA has approved Soliris®...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
21 JUL 2023 | EU | CHMP adopts positive opinion for three biosimilars The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
